Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Boston Scientific Corp. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Boston Scientific Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
The analysis of quarterly financial ratios reveals several noteworthy trends in operational efficiency over the observed periods. The inventory turnover ratio exhibits moderate fluctuations with a peak in late 2020, indicating improved inventory management during that period, followed by a gradual decline to the lowest ratio by early 2023. This trend correlates with the average inventory processing period, which shows an increase in days toward the end of the timeline, suggesting slower inventory movement.
The receivables turnover ratio maintains relative stability with minor variances, reflecting consistent credit and collection practices. Correspondingly, the average receivable collection period remains steady around the mid-50s in days, indicating no significant change in the speed of collecting receivables.
Payables turnover presents more volatility, with notable spikes in mid-2020 indicating accelerated payment to suppliers, followed by a gradual reduction in turnover rates. This behavior is mirrored by the average payables payment period, where days decrease sharply during mid-2020 and then increase gradually, suggesting a changing payment strategy or supplier terms over time.
Working capital turnover shows marked volatility, including an exceptionally high figure in late 2019 and early 2022, which may indicate extraordinary circumstances affecting working capital usage. Excluding these outliers, the turnover ratio tends to hover within a moderate range, indicating occasional shifts in how effectively working capital is deployed to support sales.
Examining the operating cycle, there is a general trend of elongation in days toward the latest periods, stemming from slower inventory processing and receivable collection. This extended cycle impacts the cash conversion cycle, which reflects the net duration of cash being tied up in the business operations. The cash conversion cycle shows a considerable decrease during 2021, pointing to improved operational cash flow management, but it lengthens again toward early 2023, signaling increasing cash flow constraints.
Overall, the data suggests that while the company demonstrated efficiency improvements in inventory and cash conversion during 2020 and parts of 2021, recent periods have shown signs of operational slowdown, with longer processing periods and a longer cash conversion cycle. The fluctuations in payables turnover and payment period indicate shifts in supplier payment timing, which may affect liquidity management. The working capital turnover's variability highlights episodic changes in managing current assets and liabilities relative to sales. These trends may warrant further investigation to optimize operational efficiency and working capital management going forward.
- Inventory Turnover and Processing Period
- Moderate fluctuations with a peak in 2020; inventory movement slows toward early 2023, as indicated by increased processing days.
- Receivables Turnover and Collection Period
- Stable with minor variations; consistent collection period around 55–60 days.
- Payables Turnover and Payment Period
- Volatile with a mid-2020 acceleration in payments; payment period decreases then gradually increases toward early 2023.
- Working Capital Turnover
- Significant volatility with occasional spikes indicating changing working capital utilization efficiency.
- Operating Cycle and Cash Conversion Cycle
- Operating cycle lengthens over time, affecting cash conversion cycle which improves in 2021 but worsens again in 2023, reflecting cash flow timing challenges.
Turnover Ratios
Average No. Days
Inventory Turnover
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cost of products sold | |||||||||||||||||||||||
| Inventories | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Inventory turnover
= (Cost of products soldQ1 2023
+ Cost of products soldQ4 2022
+ Cost of products soldQ3 2022
+ Cost of products soldQ2 2022)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Cost of Products Sold
- The cost of products sold displays a general upward trend throughout the observed periods. Starting from 730 million US dollars in March 2019, there is a noticeable increase leading up to a peak of 1040 million by March 2023. Some quarters show small fluctuations, such as a slight dip in June 2020 and March 2021, but the overall trajectory indicates increasing production or procurement costs over the four-year span.
- Inventories
- The inventory levels exhibit a steady increase from 1228 million US dollars in March 2019 to 2050 million by March 2023. Although minor short-term decreases occur, particularly around mid to late 2020, the broader pattern shows accumulation of inventory over time. This rise suggests either a buildup of stock or possibly slower inventory turnover relative to purchase rates.
- Inventory Turnover Ratio
- The inventory turnover ratio demonstrates variability with a slight declining trend towards the end of the timeline. Initially at 2.34 in March 2019, the ratio dips to its lowest point around 1.91 in September 2019, before improving to a peak of 2.59 in June 2021. Post this peak, the ratio gradually decreases again, reaching 1.97 by March 2023. The fluctuations indicate changes in the efficiency of inventory management, with somewhat less frequent turnover of stock in recent quarters compared to earlier periods.
- Summary
- Overall, the data reflects rising cost of goods sold and growing inventory holdings over the four-year span. Despite periods of improvement, inventory turnover ratios trend downward in the latest periods, suggesting that inventory may not be converting to sales as quickly as before. This could imply potential challenges in sales pace, inventory management efficiency, or changes in supply chain dynamics. Continuous monitoring and targeted strategies may be warranted to optimize inventory levels relative to cost and sales performance.
Receivables Turnover
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net sales | |||||||||||||||||||||||
| Trade accounts receivable, net | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Receivables turnover
= (Net salesQ1 2023
+ Net salesQ4 2022
+ Net salesQ3 2022
+ Net salesQ2 2022)
÷ Trade accounts receivable, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Sales Trend
- Net sales exhibited moderate fluctuations over the analyzed periods. Beginning at approximately $2.5 billion in the first quarter of 2019, sales increased steadily towards the end of that year, peaking near $2.9 billion. Thereafter, a notable decline occurred in the first half of 2020, likely reflecting external economic challenges, reaching a low near $2 billion. A recovery phase followed, with sales progressively rising through 2021 and 2022, reaching around $3.2 billion by the end of 2022 and continuing upward into the first quarter of 2023.
- Trade Accounts Receivable, Net
- Trade accounts receivable generally mirrored the net sales trend but with less volatility. Starting from approximately $1.6 billion early in 2019, receivables increased gradually throughout 2019, followed by a reduction during early to mid-2020. Subsequently, a consistent upward trajectory was observed through 2021 into 2023, indicating increased credit extended to customers in line with rising sales. By the first quarter of 2023, receivables approached $2.1 billion.
- Receivables Turnover Ratio
- The receivables turnover ratio experienced fluctuations indicative of changes in collection efficiency relative to sales. The ratio decreased from 6.13 at the start of 2019 to around 5.79 later that year, suggesting a slight easing in collection speed. This was followed by a peak near 6.97 in mid-2020, indicating improved collection efficiency despite the reduction in sales. Post mid-2020, the ratio oscillated mostly between 6.2 and 6.8, showing relatively stable and moderate collection performance. Toward the first quarter of 2023, a slight decline to 6.28 suggests a modest slowdown in receivables turnover compared to previous quarters.
- Overall Insights
- The data suggests that sales faced disruption in early 2020 but recovered strongly thereafter. Receivables grew in alignment with sales increases, while the turnover ratio maintained a relatively stable range, reflecting consistent credit management practices. The temporary upward spike in turnover ratio in mid-2020 may point to heightened collection efforts during the period of lower sales. Recent trends show continued growth in sales and receivables, though with a slight softening in turnover efficiency early in 2023.
Payables Turnover
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Cost of products sold | |||||||||||||||||||||||
| Accounts payable | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Payables turnover
= (Cost of products soldQ1 2023
+ Cost of products soldQ4 2022
+ Cost of products soldQ3 2022
+ Cost of products soldQ2 2022)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends across the periods under review.
- Cost of Products Sold
- The cost of products sold demonstrates a generally increasing trend over the years, with values rising from 730 million US dollars in March 2019 to 1,040 million US dollars by March 2023. The series shows some fluctuations within each year but with an overall upward trajectory, particularly marked by a significant increase toward the end of 2020 and sustaining at higher levels into 2022 and early 2023.
- Accounts Payable
- Accounts payable exhibit variability but an overall increase from 498 million US dollars in March 2019 to 868 million US dollars in March 2023. The data also shows a dip in mid-2020, aligning with global economic challenges, followed by recovery and consistent growth afterwards. The increases in accounts payable correspond with the rising cost of products sold, suggesting proportional growth in supplier obligations.
- Payables Turnover Ratio
- The payables turnover ratio shows a fluctuating but generally declining pattern, starting at 5.76 in March 2019 and dropping to around 4.65 by March 2023. There are peaks around mid-2020 (notably at 7.9), indicating periods where payables were paid more quickly, possibly reflecting improved payment efficiency or changed credit terms. However, the subsequent decline indicates a slowing in payment speed relative to purchases, which may affect liquidity or reflect extended payment terms.
Overall, the data indicates increasing operational scale, as evidenced by rises in cost of products sold and accounts payable, alongside changes in payment behavior as reflected in the payables turnover ratio. The company experienced periods of more rapid payment followed by slower payables turnover, implying strategic or operational adjustments in managing supplier payments during the timeframe.
Working Capital Turnover
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||||
| Working capital | |||||||||||||||||||||||
| Net sales | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Working capital turnover
= (Net salesQ1 2023
+ Net salesQ4 2022
+ Net salesQ3 2022
+ Net salesQ2 2022)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The working capital exhibits notable fluctuations over the periods analyzed. Starting with a relatively strong position at the end of March 2019, there is a marked decline by December 2019, where working capital turns negative, indicating a potential liquidity concern during that quarter. Subsequently, from March 2020 onward, working capital progressively increases, peaking around the end of 2020, before experiencing moderate volatility but generally maintaining a positive trend. This suggests an improvement in the company's short-term financial health following the dip in 2019.
Net sales demonstrate a growth trajectory with some variability. There is an initial rise from the first quarter of 2019 through the end of that year, followed by a decrease in the first two quarters of 2020, likely reflecting external economic impacts during that period. From the third quarter of 2020 onward, net sales recover and continue to rise consistently, reaching the highest level by the first quarter of 2023. This overall upward trend indicates strengthening revenue performance over the examined timeframe.
Working capital turnover, which measures efficiency in using working capital to generate sales, shows significant volatility. Extremely high turnover ratios occur in some quarters, particularly in September 2019 and March 2022, which may relate to the low or negative working capital during these periods, artificially inflating the ratio. In general, turnover ratios tend to be lower during periods when working capital is high and stabilize around mid-range values in more recent periods. This pattern suggests fluctuations in operational efficiency possibly linked to changes in working capital management or sales volumes.
- Working Capital Analysis
- Substantial variation is observed, including a negative balance in late 2019, followed by recovery and stabilization at positive levels.
- Net Sales Analysis
- Initial growth disrupted by a sales decline in early 2020, with a continuous recovery and growth from mid-2020 through early 2023.
- Working Capital Turnover Analysis
- Highly volatile ratios with spikes correlating to periods of low or negative working capital, indicating inconsistent efficiency in utilizing working capital to drive sales.
Average Inventory Processing Period
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
- Inventory Turnover Ratio
- The inventory turnover ratio exhibits noticeable fluctuations over the observed periods. Initially, it decreases from 2.34 in March 2019 to a low of 1.91 by September 2019, suggesting a slowdown in inventory movement. A recovery phase follows, with the ratio rising steadily through 2020, reaching a peak of 2.59 by June 2021. Post this peak, the ratio faces a declining trend, gradually decreasing to 1.97 by March 2023. This overall pattern indicates periods of both strengthening and weakening efficiency in managing inventory sales cycles.
- Average Inventory Processing Period (Days)
- The average inventory processing period closely aligns with the inventory turnover ratio trends, varying inversely as expected. The period increases from 156 days in March 2019 to a peak of 191 days in September 2019, reflecting slower inventory clearance during that time. Subsequently, the period declines to a minimum of 141 days in June 2021, indicating improved processing speed. However, from that point forward, the processing period lengthens again, rising to 185 days by March 2023, consistent with the observed decline in inventory turnover.
- Overall Insights
- There is a clear correlation between inventory turnover and processing period, with efficiency improving through mid-2021 followed by a deterioration extending into early 2023. The initial slowdown before 2020 could have been influenced by operational challenges or market conditions impacting inventory movement. The subsequent improvement suggests enhanced inventory management or stronger sales performance during that time. The recent downward shift indicates renewed challenges in maintaining inventory efficiency, potentially pointing to supply chain issues, shifting demand, or changes in product mix that affect the inventory cycle negatively.
Average Receivable Collection Period
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
- Receivables Turnover
- The receivables turnover ratio exhibits fluctuation over the analyzed period. Initially, the ratio decreased slightly from 6.13 to 5.79 in the first three quarters of 2019, indicating a mild decline in the efficiency of receivables collection. However, a notable improvement is seen in early 2020, peaking at 6.97 in June 2020. Thereafter, the turnover ratio fluctuates in a narrower range, settling around 6.2 to 6.8 through 2021 and 2022, with a slight decreasing trend towards early 2023 where it reaches 6.28. Overall, despite some volatility, the ratio indicates a relatively stable receivables management with slight efficiency gains centered around mid-2020.
- Average Receivable Collection Period
- The average collection period inversely mirrors the receivables turnover trend. It begins at 60 days in March 2019, rising slightly to 63 days by September 2019, suggesting a slight delay in collections. Starting in the first quarter of 2020, the collection period shortens significantly to approximately 52-53 days in the middle of 2020, indicating improved collection efficiency. Following that, the period fluctuates moderately between 53 and 59 days through 2021 and 2022, with a slight upward tick near the end of 2022 and early 2023, ending at 58 days in March 2023. This pattern suggests that while overall collection efficiency improved in 2020, there have been minor setbacks or stabilization in the months that followed.
- Summary of Trends and Insights
- The data reveals that receivables management saw improvement beginning in early 2020, which is reflected by increased receivables turnover and decreased collection days. This trend potentially indicates enhanced credit policies, improved cash collections, or changes in customer payment behavior during that period. Subsequent periods show stabilization but with slight reversals, implying the company faces challenges in maintaining peak collection efficiencies. The changes are moderate and suggest ongoing management attention is needed to sustain or further improve receivables turnover and reduce the average collection period.
Operating Cycle
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The financial data reflects key operational efficiency metrics over multiple quarters, highlighting trends in inventory management, receivables collection, and the overall operating cycle.
- Average Inventory Processing Period
- The inventory processing period exhibited a fluctuating trend over the observed timeline. Initially, it increased from 156 days at the start of the period to a peak of 191 days in the third quarter of 2019, indicating slower inventory turnover. Subsequently, there was a gradual decline, reaching its lowest point at 141 days in the second quarter of 2021, suggesting improved efficiency in inventory processing. However, from mid-2021 onwards, the period trended upward again, rising to 185 days by the first quarter of 2023, implying a slowdown in inventory turnover towards the latest period.
- Average Receivable Collection Period
- The collection period for receivables displayed relative stability with minor fluctuations across the quarters. Beginning near 60 days, it decreased notably in early 2020 to an average around 52-56 days, indicating enhanced collection efficiency during that time. From mid-2021 through the first quarter of 2023, the period oscillated between 54 and 58 days, showing consistent performance in receivables management without significant improvement or deterioration.
- Operating Cycle
- The operating cycle, representing the sum of the inventory processing and receivable collection periods, followed a pattern similar to the inventory period due to its influence on overall operations. It escalated from 216 days in early 2019 to a peak of 254 days in the third quarter of 2019, signifying extended working capital requirements during that period. Thereafter, the cycle contracted steadily until mid-2021, reaching approximately 196 days, indicating better overall operational efficiency. From then until the first quarter of 2023, the operating cycle expanded once again, increasing to 243 days, which points to a lengthening in the time taken to convert resources into cash.
In summary, while the receivable collection period remained fairly stable throughout the analysis period, fluctuations in the inventory processing period primarily drove changes in the operating cycle. Recent periods suggest a reversal of prior gains in inventory efficiency, resulting in longer operating cycles and potentially increased capital constraints.
Average Payables Payment Period
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
- Payables Turnover
- The payables turnover ratio exhibits fluctuations across the observed periods. Initially, the ratio remained relatively stable around the mid-5 range during 2019. A notable increase occurred in the first three quarters of 2020, peaking at 7.9 in the second quarter of 2020, followed by a gradual decline through the end of 2020. Throughout 2021, the ratio generally declined, reaching a low of 4.67 in the fourth quarter. The trend continued with a slight but consistent decrease in 2022 and into the first quarter of 2023, stabilizing around 4.6.
- Average Payables Payment Period
- The average payables payment period in days inversely corresponds with the payables turnover ratio. During 2019, it fluctuated narrowly between 62 and 66 days. In 2020, the payment period dropped sharply to a low of 46 days in the second quarter, indicating quicker payments, then gradually increased to 54 days by the end of the year. The year 2021 saw an increase in the payment period, peaking at 78 days in the fourth quarter. This lengthening of payment times continued through 2022, reaching up to 80 days in the fourth quarter and remaining high at 78 days in the first quarter of 2023.
- Overall Insights
- The analysis reveals a phase of faster payment cycles during mid-2020, coinciding with the peak in payables turnover ratio. Subsequently, a gradual lengthening of the payment period has occurred through 2021 to early 2023, reflected by decreasing turnover ratios. This pattern suggests a shift toward more extended payment terms or slower settlement of payables in recent quarters. The steady increase of days payable outstanding may impact cash flow management and supplier relationships and should be monitored in the context of broader operational strategy and liquidity conditions.
Cash Conversion Cycle
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q1 2023 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
- Average Inventory Processing Period
- The average inventory processing period demonstrated a generally fluctuating trend over the observed quarters. Beginning at 156 days in early 2019, it increased steadily to peak at 191 days in September 2019. Following this peak, there was a gradual decline through 2020, reaching its lowest point of 142 days in December 2020. However, from 2021 onwards, the period showed some variability but a trend toward increasing days was notable, reaching 185 days by March 2023. This indicates cycles of inventory holding times with significant elongation in some quarters, particularly toward the end of the period analyzed.
- Average Receivable Collection Period
- The average receivable collection period remained relatively stable throughout the timeframe, fluctuating between approximately 52 and 63 days. An initial decline is observed from around 60 days in early 2019 to the low 50s during mid-2020, potentially reflecting improved collection efficiency during that time. However, the collection period tended to vary modestly around the mid-50s to upper 50s mark thereafter. Such stability suggests consistent credit and collection policies with minor operational variations.
- Average Payables Payment Period
- The average payables payment period experienced notable fluctuations. Starting near the low 60s in 2019, the period dropped sharply to 46 days in mid-2020, indicating a faster payment schedule during that time. Subsequently, the payment period increased steadily, surpassing 70 days in several quarters across 2021 and 2022, and reaching up to 80 days by late 2022. This pattern may reflect strategic adjustments in payment terms or cash flow management, allowing the company to extend payment timing in later periods.
- Cash Conversion Cycle
- The cash conversion cycle (CCC) exhibited considerable variation aligning broadly with movements in inventory and payables periods. The CCC peaked at 192 days in the third quarter of 2019, correlating with the high inventory processing period. A marked reduction occurred by the end of 2020, lowering to 128 days, facilitated by shorter inventory and payables periods. From 2021 through early 2023, the CCC fluctuated primarily between 135 and 165 days, indicating moderate cyclical adjustments but no definitive long-term improvement or deterioration. This suggests the company's working capital efficiency experienced periods of both tightening and easing during the observed timeframe.